1 October 2024 v2026.22.1 limited_company_frs_102_section_1a_v1_1_3 companies_houseSoftwarefalsetruetruetrueNo description of principal activity00falsetruexbrli:purexbrli:sharesiso4217:GBP032007492024-10-012025-09-30032007492025-09-30032007492024-09-3003200749core:WithinOneYear2025-09-3003200749core:WithinOneYear2024-09-3003200749core:ShareCapital2025-09-3003200749core:ShareCapital2024-09-3003200749core:RetainedEarningsAccumulatedLosses2025-09-3003200749core:RetainedEarningsAccumulatedLosses2024-09-3003200749bus:Director12024-10-012025-09-3003200749bus:RegisteredOffice2024-10-012025-09-3003200749core:MotorVehicles2024-10-012025-09-300320074912024-10-012025-09-30032007492023-10-012024-09-3003200749countries:EnglandWales2024-10-012025-09-3003200749bus:AuditExemptWithAccountantsReport2024-10-012025-09-3003200749bus:PrivateLimitedCompanyLtd2024-10-012025-09-3003200749bus:SmallEntities2024-10-012025-09-3003200749bus:AbridgedAccounts2024-10-012025-09-30
Company registration number:
03200749
Pharmat Limited
Unaudited Filleted Abridged Financial Statements for the year ended
30 September 2025
Pharmat Limited
Abridged Statement of Financial Position
30 September 2025
20252024
££
Current assets    
Debtors
780,425
 
778,598
 
Cash at bank and in hand
67
 
67
 
780,492
 
778,665
 
Creditors: amounts falling due within one year
(3,247
 )
(2,918
 )
Net current assets
777,245
 
775,747
 
Total assets less current liabilities 777,245   775,747  
Capital and reserves    
Called up share capital
2
 
2
 
Profit and loss account
777,243
 
775,745
 
Shareholders funds
777,245
 
775,747
 
For the year ending
30 September 2025
, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
  • The members have not required the company to obtain an audit of its abridged financial statements for the year in question in accordance with section 476;
  • The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of abridged financial statements.
All of the members have consented to the preparation of the abridged statement of financial position for the year ended
30 September 2025
in accordance with Section 444(2A) of the Companies Act 2006.
These
abridged financial statements
have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies’ regime.
In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered.
These
abridged financial statements
were approved by the board of directors and authorised for issue on
12 June 2026
, and are signed on behalf of the board by:
Mr S Hiwaizi
Director
Company registration number:
03200749
Pharmat Limited
Notes to the Abridged Financial Statements
Year ended
30 September 2025

1 General information

The company is a private company limited by shares and is registered in England and Wales. The address of the registered office is
149 Edgware Road
,
London
,
W2 2HU
, England.

2 Statement of compliance

These
abridged financial statements
have been prepared in compliance with FRS 102 Section 1A, 'The Financial Reporting Standard applicable to the UK and Republic of Ireland'.

3 Accounting policies

Basis of preparation

The
abridged financial statements
have been prepared on the historical cost basis, as modified by the revaluation of certain assets.
The
abridged financial statements
are prepared in sterling, which is the functional currency of the company.

Current tax

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Tangible assets

Tangible assets are initially measured at cost, and are subsequently measured at cost less any accumulated depreciation and accumulated impairment losses or at a revalued amount.
Any tangible assets carried at a revalued amount are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
An increase in the carrying amount of an asset as a result of a revaluation is recognised in other comprehensive income and accumulated in capital and reserves. However, the increase is recognised in profit or loss to the extent that it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves. If a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess is recognised in profit or loss.
Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:
Motor vehicles
25% reducing balance

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.
Basic financial instruments are initially recognised at the transaction price and are subsequently measured as follows: Debt instruments are subsequently measured at amortised cost and commitments to receive a loan and to make a loan to another entity are subsequently measured at amortised cost.
All other financial instruments, including derivatives, are initially recognised at fair value, which is normally the transaction price and are subsequently measured at fair value, with any changes recognised in profit or loss.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.
All equity instruments regardless of significance, and other financial assets that are individually significant, are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics.

4 Average number of employees

The average number of persons employed by the company during the year was nil (2024: nil).

5 Fixed assets

Tangible assets
£
Cost  
At
1 October 2024
and
30 September 2025
7,500
 
Depreciation  
At
1 October 2024
and
30 September 2025
7,500
 
Carrying amount  
At
30 September 2025
 -  
At 30 September 2024 -  

6 Director's advances, credit and guarantees

At the year end, the director owed the company £119,010 (2024: £116,643).